Revance Therapeutics Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines
October 01, 2014 at 16:02 PM EDT
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and ...